Therapeutic | Blinatumomab |
Target 1 | CD19 |
Heavy Chain 1 | QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS |
Light Chain 1 | DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | CD3E |
Heavy Chain 2 | DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS |
Light Chain 2 | DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific T-Cell Engager |
Isotype | na |
Highest Clinical Trial (Jan '20) | Approved |
Estimated Status (Jan '20) | Active |
Recorded Developmental Technology | BiTE Technology |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | Amgen, Astellas Pharma, M. D. Anderson Cancer Center, Merck & Co, Micromet Inc, National Cancer Institute (USA), University of California Davis |
Conditions Approved | Precursor B-cell lymphoblastic leukaemia-lymphoma |
Conditions Active | Non-Hodgkin's lymphoma, Diffuse large B cell lymphoma |
Conditions Discontinued | Chronic lymphocytic leukaemia |
Notes |